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ABSTRACT
We present a case of beta-propeller protein-associated neurodegeneration, a form of neurodegeneration with brain iron accu-
mulation. The patient harbored a novel mutation in the WDR45 gene. A detailed video and description of her clinical condition 
are provided. Her movement disorder phenomenology was characterized primarily by limb stereotypies and gait dyspraxia. The 
patient’s disability was advanced by the time iron-chelating therapy with deferiprone was initiated, and no clinical response in 
terms of cognitive function, behavior, speech, or movements were observed after one year of treatment. 
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Beta-propeller protein-associated neurodegeneration (BPAN) 
is a form of neurodegeneration with brain iron accumulation 
(NBIA; type 5), which was initially described as static encepha-
lopathy of childhood with neurodegeneration in adulthood 
(SENDA). BPAN is very rare, with fewer than 50 cases report-
ed to date.1 The disease typically starts in early childhood with 
intellectual impairment and seizures. The disease progresses 
during adolescence or early adulthood with the emergence of 
dementia and movement disorders, especially dystonia and 
parkinsonism.1,2 Rett syndrome-like behaviors, including hand 
stereotypies, may be observed. The vast majority of cases are 
female and sporadic, resulting from a de novo mutation in the 
WD repeat-containing protein 45 (WDR45) gene located at 
Xp11.23.1,2 The gene product, WIPI4, is a 7-bladed beta-pro-
peller protein believed to be involved in autophagy, and there 
is preliminary evidence suggesting that BPAN could be a 
tauopathy.3 
We report a case of a 29-year-old woman of ethnic Indian 
descent with typical imaging results and clinical presentation 
for BPAN (intellectual impairment, epilepsy beginning with 
febrile seizures, Rett-like features, including loss of language, 
and the presence of stereotypies and gait dyspraxia) as well as  a 
novel mutation in the WDR45 gene (c.249G>A in exon 6). To 
the best of our knowledge, this is only the second patient of 
ethnic Indian descent reported with BPAN.4 A detailed video 
and description of her clinical condition are provided. Our ex-
perience with deferiprone treatment is also described; we are 
aware of only one prior case report of a BPAN patient treated 
with deferiprone. 
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She could speak in brief sentences but was never 
able to read or write. 
In her early 20s, she started to deteriorate with re-
duced ability to walk and was falling backwards, fol-
lowed soon after by cognitive decline. Ophthalmo-
logical examination revealed optic atrophy without 
retinal pigmentary changes. EEG showed theta-
delta range slowing of the background rhythm with 
epileptiform discharges. Brain MRI repeated at age 
24 (Figure 1, lower panel) showed marked bilateral 
T2 hypointensity in the substantia nigra and globus 
pallidus and a “slit” of T1 hypointensity in the nigra 
with a faint rim of hyperintensity, as well as global 
cerebral atrophy and cerebellar atrophy. Brain mag-
netic resonance spectroscopy was normal. Molecular 
genetic testing revealed a nucleotide change of gua-
nine (G) to adenine (A) at nucleotide position c.249 
(c.249G>A) in exon 6 in one copy of the WDR45 
gene (accession number NM 007075.3) (Knight 
Diagnostic Laboratories, Knight Cancer Institute, 
Oregon Health and Science University, Portland, 
OR, USA). This variant is not annotated in any pub-
lished database, including Exome Aggregation Con-
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The patient was the second child of a nonconsan-
guineous couple. Birth and early developmental 
history were unremarkable. There was no history of 
neurological disorders in the immediate or extend-
ed family. At 13 months of age, she started having 
seizures associated with fever and urinary tract in-
fections. The seizures became more frequent dur-
ing her early childhood and were described as epi-
sodes of absence, brief jerks, or sudden forward 
flexion of the trunk. She became hyperactive with 
poor attention span and was diagnosed with a 
learning disability. EEG revealed epileptiform dis-
charges, but brain MRI results were reportedly nor-
mal (although in retrospect, bilateral T2 hypointen-
sity could be seen in the substantia nigra) (Figure 1, 
top panel). She was treated with clonazepam and 
methylphenidate. At the age of eight, sodium val-
proate and levetiracetam were added, and the sei-
zures were controlled. She attained her best level of 
function in her teenage years. She was able to walk 









Figure 1. Brain MRI scans performed at ages eight (top panel) and 24 (bottom panel). The first MRI was initially 
reported as normal but in retrospect shows bilateral T2 hypointensity in the substantia nigra (A). However, the first 
MRI shows normal signal in the globus pallidus (B) (more prominent nigral vs. pallidal involvement is typical of be-
ta-propeller protein-associated neurodegeneration).1 There is also mild thinning of the posterior corpus callosum, 
seen on the sagittal T1 image (not shown). Later, marked T2 hypointensity in the substantia nigra and cerebral pe-
duncle (arrow) (E) and globus pallidus (arrow) (F) has developed bilaterally. There is a “slit” of T1 hypointensity in 
the nigra with a faint rim of hyperintensity,  the so-called “halo” sign (arrow) (G), as well as global cerebral atrophy (G 
and H, compared to C and D) and cerebellar atrophy (arrowhead) (G).
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sortium (ExAC), 1000 Genomes, or the National 
Heart, Lung and Blood Institute Exome Sequencing 
Project Exome Variant Server (EVS). This mutation 
predicts an amino acid change of tryptophan (Trp) 
to a stop codon at codon p.83 (p.Trp83X) (accession 
number NP 009006) within the WD40 repeat do-
main of WDR45. Additionally, this mutation is pre-
dicted to be pathogenic, potentially resulting in a 
truncated WDR45 protein, which lacks amino acids 
84–361.5 Proteomic analysis may be explored in the 
future to confirm the truncation. Both parents tested 
negative for the mutation, and screening of an ad-
ditional 20 control samples from the local popula-
tion was negative. Her older sister, who lives overseas, 
also had a negative genetic test result. The patient’s 
other blood investigations were normal, including 
blood film (no acanthocytes) and lactate.
Upon treatment with sodium valproate (200 mg 
bid), levetiracetam (500 mg bid), baclofen (10 mg 
bid), trihexyphenidyl (1.5 mg daily), and clonaze-
pam (0.5 mg bid), her seizures were controlled, and 
episodic limb muscle spasms were reduced. Previ-
ous trials of levodopa treatment resulted in general-
ized dyskinesia and had to be stopped. Her condition 
when age 28–29 is shown in the video and described 
in the video legend (please see Supplementary Video 
1 in the online-only data supplement). 
A trial of deferiprone, an iron-chelating agent able 
to cross the blood-brain barrier, was initiated at a 
dose of 250 mg bid (body weight 65 kg). When this 
was uptitrated to 500 mg bid,  i.e. approximately 15 
mg/kg/day (a moderate 20–30 mg/kg/day dose has 
been suggested for chelation in neurodegenerative 
disorders, whereas typically approximately 80 mg/
kg/day is used to treat iron overload due to blood 
transfusion in thalassemia),6-8 the patient experi-
enced distressing abdominal pain, anorexia, insom-
nia, restlessness, and agitation, and the treatment 
had to be withheld. Deferiprone was subsequently 
resumed and gradually increased to 250 mg bid, but 
she again suffered the same side effects as before. 
Thus, the dosage had to be reduced back to 250 mg 
daily. After treatment with deferiprone for a year, 
there has been no apparent clinical improvement in 
terms of cognitive function, behavior, speech, or 
movements. The patient’s symptomatic treatments 
remained stable over this period. Repeat brain imag-
ing was not performed, as this would have necessi-
tated administration of general anesthesia.
Interestingly, iron indices prior to initiation of 
deferiprone showed low systemic iron stores with 
transferrin saturation of 10% (reference range 20– 
45%); the serum ferritin level (52.9 µg/L,  reference 
range 10.0–291.0 µg/L), hemoglobin level  (121 g/L), 
and mean corpuscular volume (81 fL) were in the 
lower range of normal. There was no history of men-
orrhagia or other overt blood loss, and serum vita-
min B12 and folate levels were in the normal range. 
We were concerned about the possibility of induc-
ing global iron depletion in a patient who was al-
ready mildly hypoferremic; however, her transferrin 
saturation and ferritin levels (ranged between 19–
20% and 53.7–67 µg/L, respectively) did not drop 
further during deferiprone treatment . 
DISCUSSION 
We report a case of BPAN with a novel mutation 
in the WDR45 gene with illustrative video and de-
tailed description of the movement disorder phe-
nomenology, characterized primarily by limb stereo-
typies and gait dyspraxia. Sequential brain imaging 
showed evolution of iron deposition and atrophy 
over time, with involvement of the substantia nigra 
occurring earlier and more prominently than in the 
pallidum, as previously described.1 
Chelation therapy with deferiprone to remove ex-
cessive iron in the brain has shown some promise 
in pantothenate kinase-associated neurodegenera-
tion (PKAN), the most common form of NBIA. In 
one study (n = 9), treatment for 6 months resulted in 
improvement of radiological but not clinical status; 
the authors noted that the majority of their patients 
were already in an advanced stage (e.g., wheelchair-
bound) by the time of treatment initiation.7 Another 
cohort of patients (n = 6) with  milder disability over-
all compared to the aforementioned study completed 
3–4 years of treatment. This cohort showed radio-
logical improvement and stabilization of motor 
symptoms.8 However, convincing evidence of clini-
cal benefit is lacking. No serious adverse events were 
reported.7,8 Unfortunately, although perhaps not un-
expectedly since she was already severely disabled by 
the time of deferiprone initiation, our patient did 
not show any clinical response to treatment after 
one year. Furthermore, only a low dose of deferiprone 
could be used due to poor patient tolerance. We are 
aware of only one other published case report of a 
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their consent and participation in this report, including publica-
tion of the video. SAS was supported by the Else Kröner-Frese-
nius Stiftung.
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patient with BPAN (with much milder motoric im-
pairment compared to our patient) who was treated 
with deferiprone at a relatively high dose of 1,000 
mg bid for four months. The treatment coincided 
with worsening of the patient’s parkinsonian fea-
tures and was ceased for this reason.9 
This case adds to the existing literature on a very 
rare neurodegenerative disease. It is hoped that great-
er awareness of the NBIAs, including rare forms such 
as BPAN, will lead to future advances in the scientif-
ic understanding and management of these disabling 
diseases.10
Supplementary Video Legends
Video 1. The patient has an “open mouth” facies with a vacu-
ous smile and inappropriate laughter. Speech is limited to high-
pitched sounds and simple single words (e.g., saying “cry” 
when she is apparently happy), and comprehension is severely 
impaired (e.g., unable to follow verbal or gestural commands 
to perform repetitive movements when testing for limb brady-
kinesia). Spontaneous eye movements are normal. Midline ste-
reotypies in the hands (e.g., fiddling with an object and hand 
tapping) are seen. There is abnormal posturing (e.g., intermit-
tently crossing the left leg,  sometimes even while she is walk-
ing, or holding the arms raised above her head).  Although, 
these look volitional rather than dystonic (likely also represent-
ing stereotypies). In the third video segment, intermittent cho-
reiform movements occur in the right leg, which again proba-
bly represent stereotypies. A strong grasp response is present 
bilaterally (e.g., patient reaching out for the examiner’s hand); 
pollicomental and palmomental reflexes are also present bilat-
erally (not shown). The patient is only able to stand and walk 
with 2-person assistance (requiring support from the back to 
prevent backward falls) in an unusual high-stepping or march-
ing fashion—probably best classified as a gait dyspraxia. Mod-
erate cogwheel rigidity is present at the wrists, as well as mild 
rigidity in the left leg. However, spontaneous movements do 
not appear bradykinetic, and there is no resting or postural 
tremor. There are no pyramidal signs.
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The online-only Data Supplement is available with this arti-
cle at https://doi.org/10.14802/jmd.17082.
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